HC Wainwright Cuts Earnings Estimates for Tyra Biosciences

Tyra Biosciences, Inc. (NASDAQ:TYRA – Free Report) – Equities researchers at HC Wainwright lowered their FY2026 earnings estimates for shares of Tyra Biosciences in a report issued on Wednesday, November 11th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings per share of ($2.64) for the year, down from their previous estimate of ($2.60). HC Wainwright has a “Buy” rating and a $27.00 price target on the stock. The consensus estimate for Tyra Biosciences’ current full-year earnings is ($2.77) per share. HC Wainwright also issued estimates for Tyra Biosciences’ Q4 2026 earnings at ($0.59) EPS, Q1 2027 earnings at ($0.59) EPS, Q2 2027 earnings at ($0.61) EPS, Q3 2027 earnings at ($0.61) EPS, Q4 2027 earnings at ($0.62) EPS and FY2027 earnings at ($2.44) EPS.

Tyra Biosciences (NASDAQ:TYRA – Get Free Report) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.07).

Other equities research analysts have also issued research reports about the stock. Piper Sandler restated an “overweight” rating and issued a $56.00 target price on shares of Tyra Biosciences in a report on Tuesday, September 8th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $50.00 price target on shares of Tyra Biosciences in a research report on Tuesday, October 6th. Oppenheimer reiterated an “outperform” rating and set a $40.00 price target (down from $50.00) on shares of Tyra Biosciences in a research note on Tuesday, September 22nd. William Blair raised Tyra Biosciences to a “strong-buy” rating in a report on Wednesday, September 23rd. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Tyra Biosciences in a research note on Thursday, September 10th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $47.40.

Read Our Latest Stock Report on TYRA

Tyra Biosciences Trading Up 1.3%

Tyra Biosciences stock opened at $20.02 on Friday. The firm has a market capitalization of $1.38 billion, a price-to-earnings ratio of -7.58 and a beta of 0.65. The firm’s fifty day moving average price is $21.75 and its two-hundred day moving average price is $29.38. Tyra Biosciences has a 1-year low of $14.84 and a 1-year high of $40.65.

Hedge Funds Weigh In On Tyra Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Bank of America Corp DE purchased a new position in shares of Tyra Biosciences in the 2nd quarter worth about $11,170,000. Walleye Capital LLC purchased a new stake in Tyra Biosciences during the second quarter worth about $11,112,000. 5AM Venture Management LLC purchased a new stake in Tyra Biosciences during the second quarter worth about $32,875,778. The Manufacturers Life Insurance Company purchased a new stake in Tyra Biosciences during the second quarter worth about $1,416,000. Finally, Squarepoint Ops LLC raised its position in Tyra Biosciences by 211.3% in the second quarter. Squarepoint Ops LLC now owns 63,805 shares of the company’s stock worth $2,038,000 after acquiring an additional 43,311 shares during the period. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Key Headlines Impacting Tyra Biosciences

These are some of the TYRA headlines that stood out recently:

  • Positive Sentiment: HC Wainwright kept its Buy rating and $27 price target, while a separate report described analysts as bullish on TYRA. The target suggests potential upside from the recently cited $20.02 price, though it is not a guarantee. Analysts Are Bullish on Top Healthcare Stocks: Claritev (CTEV), Tyra Bioscience (TYRA)
  • Neutral Sentiment: Certain restricted stock units are covered by a lock-up agreement ending November 13. The expiry could allow shares to be sold, but the report does not indicate that holders plan to sell. Restricted Stock Unit Lock-Up Agreement
  • Negative Sentiment: HC Wainwright lowered most of its 2027 quarterly and full-year EPS forecasts, including FY2027 to a loss of $2.44 per share from $2.27. Its FY2026 loss estimate also edged lower to $2.64 from $2.60, although the Q4 2026 forecast improved. These revisions signal expectations for greater near-term losses despite the continued Buy rating. HC Wainwright Estimate Changes

Tyra Biosciences Company Profile

(Get Free Report)

Tyra Biosciences, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for genetically defined diseases. Its research focuses on small-molecule therapies that target the fibroblast growth factor receptor (FGFR) family and related pathways, using a drug-discovery approach designed to address resistance and selectivity challenges. The company’s pipeline includes TYRA-300, a selective FGFR3 inhibitor being studied for conditions including achondroplasia and urothelial cancer, and TYRA-200, an FGFR inhibitor being developed for certain cancers.

Recommended Stories

Earnings History and Estimates for Tyra Biosciences (NASDAQ:TYRA)

Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.